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Colocalization of Increased Transforming Growth
Factor-–Induced Protein (TGFBIp) and Clusterin
in Fuchs Endothelial Corneal Dystrophy
Ula V. Jurkunas,1,2,3 Maya Bitar,2,3 and Ian Rawe2
PURPOSE. To investigate the differential expression of TGFBIp
in normal human and Fuchs endothelial corneal dystrophy
(FECD) endothelial cell–Descemet’s membrane (HCEC-DM)
complex, and to asses the structural role of TGFBIp and clus-
terin (CLU) in guttae formation.
METHODS. HCEC-DM complex was dissected from stroma in
normal and FECD samples. Proteins were separated by 2-D gel
electrophoresis and subjected to proteomic analysis. N-termi-
nal processing of TGFBIp was detected by Western blot anal-
ysis with two separate antibodies against the N- and C-terminal
regions of TGFBIp. Expression of TGFBI mRNA was compared
by using real-time PCR. Subcellular localization of TGFBIp and
CLU in corneal guttae was assessed by fluorescence confocal
microscopy.
RESULTS. A major 68-kDa fragment and a minor 39-kDa fragment
of TGFBIp were identified on 2-D gels. Western blot analysis
revealed an age-dependent proteolytic processing of the TGF-
BIp N terminus resulting in the increased formation of 57-kDa
(P  0.04) and 39-kDa (P  0.03) fragments in older donors.
FECD HCEC-DM showed a significant increase in the 68-kDa
(P  0.04), 57-kDa (P  0.01), and 39- kDa (P  0.03)
fragments of TGFBIp. Real-time PCR analysis revealed that
TGFBI mRNA was significantly increased (P  0.04) in FECD
samples. TGFBIp formed aggregates at the lower portions of
guttae, next to Descemet’s membrane, whereas CLU localized
mostly on top of the TGFBIp-stained areas at the level of the
endothelial cell nuclear plane.
CONCLUSIONS. The overexpression of proaggregative protein
CLU, and proadhesive protein TGFBIp, have been colocalized
in the guttae. Such findings provide us with a better under-
standing of the major contributors involved in the aberrant
cell–extracellular matrix interactions seen in the guttae of
patients with FECD. (Invest Ophthalmol Vis Sci. 2009;50:
1129–1136) DOI:10.1167/iovs.08-2525
Fuchs endothelial corneal dystrophy (FECD) is the mostcommon endogenous corneal endotheliopathy, leading to
progressive corneal edema, blindness, and eventual need for
corneal transplantation to restore vision. In early stages, FECD
is characterized by extracellular collagenous deposits that ac-
cumulate posterior to Descemet’s membrane, thicken it, and
cause the formation of mound-shaped aggregates, called “gut-
tae.” The characteristic pattern on specular microscopy show-
ing dark areas in the endothelial mosaic is due to the displace-
ment of the endothelium posterior to the plane of focus by
these excrescences. In the later stages, the coalescence of the
guttae occurs, and a progressive disruption of the endothelial
mosaic causes cell thinning, stretching, enlargement, and loss
of hexagonal shape.1 Eventually, there is a compromise in the
intact covering of the endothelial monolayer as endothelial cell
loss progresses in an inversely proportional manner to guttae
formation. The considerable strain on corneal endothelial cells
situated at the apices of these excrescences causes the mor-
phologic changes that lead to the loss of barrier function as
well as cell apoptosis, which has been widely implicated in
FECD.2 Still, the exact composition of these outgrowths or
guttae is currently not clear.
Studies from this laboratory have described the results of
2-D gel analysis of proteins extracted from human corneal
endothelial cell-Descemet’s membrane (HCEC-DM) complexes
dissected from the corneas of normal donors and patients with
FECD.3,4 These studies showed that there is a marked overex-
pression of the proaggregative, chaperone-like protein clus-
terin in FECD.3 The staining of FECD corneas with CLU anti-
bodies revealed a clustering of endothelial cells around the
guttae as well as CLU staining in the centers of the guttae,
suggesting the presence of cell remnants in these areas. Studies
have shown that under stressed conditions, CLU tends to cause
cell aggregation and induce the formation of junctional con-
tacts between cells.5 The results of the 2-D gel analysis also
demonstrated a marked overexpression of the cell adhesion
molecule TGFBIp in the FECD-affected HCEC-DM complexes.
TGFBIp was detected as a series of spots, migrating at 38
kDa. The number and intensity of these spots was greater in
FECD HCEC-DM as opposed to those in normal control sub-
jects. The purpose of the present study is to investigate further
the role of TGFBIp in the characteristic guttae formation and its
relation to CLU.
TGFBI (transforming growth factor [TGF]- induced) gene
encodes the transforming growth factor-–induced protein
(TGFBIp), an extracellular matrix protein that mediates cell
adhesion by interacting with collagens, fibronectin, and inte-
grins, mainly 31.6–10 This protein has been identified by
TGFBI gene induction with TGF- in a human adenocarcinoma
line.11 Mutations in the TGFBI gene are responsible for several
corneal stromal dystrophies, such as Lattice dystrophy type I,
Reis-Bu¨ckler dystrophy, Thiel-Behnke corneal dystrophy, gran-
ular corneal dystrophy II (Avellino corneal dystrophy), and
granular corneal dystrophy type I.12–15 Depending on the dys-
trophy, the mutation in the TGFBI gene manifest as stromal
amyloid and/or nonamyloid deposits in which TGFBI itself has
been colocalized.16 Analysis of the pathologic corneas taken
from the stromal dystrophy patients has revealed that there are
mutation-specific changes in the processing of the full-size
protein as opposed to unaffected corneas.16 In the present
study, we used immunocytochemistry to localize the TGFBIp
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deposition and to elucidate further the role of TGFBIp in guttae
formation. Also, using antibodies against two nonoverlapping
parts of the protein, we investigated whether there are
changes in the processing of TGFBIp between FECD and nor-
mal endothelial samples. To obtain greater insight into the role
of TGFBIp in the HCEC-DM complex, we also compared the




Donor confidentiality was maintained according to the Declaration of
Helsinki. This study was approved by the Massachusetts Eye and Ear
Institutional Review Board. Informed consent was obtained from pa-
tients undergoing corneal transplantation for FECD. After surgical
removal of the FECD corneal buttons, two thirds of the button was
used for the study, and one third was used for histopathologic confir-
mation of the diagnosis. Normal human corneal buttons were obtained
from the Tissue Banks International (Baltimore, MD) and National
Disease Research Interchange (Philadelphia, PA) and were used as
normal control samples. The corneas were kept in storage medium for
less than 72 hours before processing. We used our previously pub-
lished criteria for obtaining normal control subjects from the tissue
banks.3,4
Sample Preparation
Table 1 presents information regarding the normal and FECD tissue
samples. Normal donors were decade-matched with FECD. Because of
low protein or RNA content, two FECD samples contained two pooled
corneas (Table 1, samples 8 and 15). Corneal buttons were recovered
from storage medium (Optisol-GS; Bausch & Lomb Surgical, Irvine, CA)
and briefly rinsed in PBS. Under a dissecting microscope, Descemet’s
membrane along with the endothelial cell layer (HCEC-DM complex)
was dissected from the stroma and washed with 10 mM HEPES buffer
(pH 7.4) before protein extraction. Samples used for 2-D gel electro-
phoresis were subjected to an additional washing step with HEPES
buffer (10 mM, pH 7.4) to reduce the concentration of salts. Protein
extraction buffer ER3 (Bio-Rad, Hercules, CA), containing 5 M urea, 2
M thiourea, 2% CHAPS, 2% SB 3-10, 40 mM Tris, 0.2% ampholyte
(Bio-Lyte 3/10; Bio-Rad) ampholyte, and 1 mM tributyl phosphine
(TBP), was added to the HCEC-DM sample. Proteins were solubilized
by pipetting up and down to promote adequate mixing and then
incubating the samples at room temperature for 30 minutes, followed
by ultracentrifugation at 40,000 rpm, 21°C for 1 hour. HCEC-DM
protein samples were used for 2-D gel electrophoresis and Western
blot analysis. The protein concentration of the samples was deter-
mined by modified protein assay (Bio-Rad).
2-D Gel Electrophoresis and
Protein Identification
For 2-D gel electrophoresis, the sample was prepared by pooling
HCEC-DM protein extracts from five normal corneas of three donors (a
67-year-old woman, 64-year-old man, and 59-year-old man; Table 1,
sample 1). Protein extract (150 L) was loaded onto immobilized, pH
3 to 10 nonlinear gradient, 17 cm IPG strips (Bio-Rad) for passive
rehydration for 14 hours of isoelectric focusing and second-dimen-
sional separation were performed as previously reported.3,4 Gels were
then fixed in 10% methanol and 7% acetic acid, stained overnight with
a protein gel stain (SYPRO Ruby; Invitrogen, Carlsbad, CA), and
washed in water for 1 hour before imaging. Protein spots from the 2-D
gel were imaged (ProEXPRESS Proteomic Imaging System; Perkin-
Elmer, Boston, MA), using optimized excitation (480/80) and emission
(650/150) filters for the protein gel stain. Gel plugs from the protein
spots were excised by direct picking using a spot-picking robot
equipped with a CCD camera (ProXcision; PerkinElmer) and filter sets
for the red stain. Gel pieces were placed in a microtiter plate (ZipPlate;
Millipore, Billerica, MA) and processed as described in the manufac-
turer’s protocol. The identification of protein spots was performed by
MALDI-TOF, as previously described.3,4 Proteins were identified by
searching a local copy of the NCBI protein database (National Center
for Biotechnology Information, www.ncbi.nih.gov) using the Pro-
Found search engine (Rockefeller University, New York, NY).
Western Blot Analysis
Age difference in TGFBIp expression by Western blot analysis was
compared between three young (2, 15, and 18 years old) and three
older (64, 68, and 73 years old) normal donors (Table 1, samples 2–7).
TGFBIp expression was compared between five normal and FECD
HCEC-DM samples (Table 1, samples 8–12). Equal amounts of protein
were loaded on 10% bis-tris gels for SDS-PAGE. Peptides were then
electrophoretically transferred to a polyvinylidene difluoride (PVDF)
membrane (Millipore). Nonspecific binding was blocked by incubation
for 1 hour at room temperature in 5% nonfat milk diluted in PBS.
Membranes were incubated overnight at 4°C with rabbit polyclonal
anti-TGFBIp (H-58; Santa Cruz Biotechnology, Santa Cruz, CA) diluted
1:100, goat polyclonal anti-TGFBIp (E-19; Santa Cruz Biotechnology)
diluted 1:100, and mouse monoclonal anti--actin (Sigma-Aldrich, St.
Louis, MO) diluted 1:6000 in blocking solution. The anti-TGFBIp anti-
bodies were created against a recombinant TGFBIp (NCBI GI no.
2498193; National Center for Biotechnology Information, Bethesda,
MD), and molecular weight ranges were confirmed by the affinity
purification of the specific peptides by Santa Cruz Biotechnology. Blots
were rinsed, reblocked, and exposed for 1 hour to horseradish perox-
idase (HRP)–conjugated donkey anti-mouse IgG for -actin, anti-rabbit
IgG for clusterin, anti-rabbit IgG for TGFBIp (H-58), and anti-goat IgG
for TGFBIp (E-19). All secondary antibodies were obtained from Jack-
son ImmunoResearch Laboratories, Inc. (West Grove, PA) and diluted
1:2000 in blocking solution. After washing in 0.1% Triton X-100,
peptides were detected with a pico chemiluminescent substrate (Su-
perSignal; Pierce, Rockford, IL). Images were digitally scanned and
analyzed with NIH Image software version 1.61 (developed by Wayne







Age Sex Age Sex Use of Samples
1 67 F 2-D gel
64 M
59 M






8 69 M 67 F Western blot analysis
66 F 72 F
9 75 F 73 M
10 55 F 68 M
11 78 F 73 M
12 79 F 72 F
13 69 F 68 F Real-time PCR
14 59 M 69 M
15 72 M 64 F
69 F
16 64 F 65 F Immunohistochemistry
17 87 F 71 M
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Rasband, National Institutes of Health, Bethesda, MD; available at
http://rsb.info.nih.gov/ij/index.html). Protein was normalized accord-
ing to -actin and total protein content. Experiments were repeated at
least two times. Results were averaged and the standard deviation
calculated. Statistical analysis by Student’s unpaired t-test was per-
formed (Excel 2002 for Windows XP; Excel, Redmond, WA). P  0.05
was considered to be significant.
Real-Time PCR
Total RNA was extracted from normal and FECD HCEC-DM complexes
(samples 13–15, Table 1) as recommended by the manufacturer
(TRIzol; Invitrogen). Samples were purified from DNA contamination
by treating them with amplification grade DNase I (Invitrogen). RNA
quantity and quality were assessed by spectrophotometric analysis. For
all samples, cDNA was prepared by reverse transcription with a com-
mercially available kit (Promega, Madison, WI). Relative expression
levels of TGFBI were assessed by real-time PCR with a sequence-
detection system (ABI Prism model 7900 HT; Applied Biosystems Inc.,
[ABI] Foster City, CA). Primers and probes for TGFBI (TaqMan Gene
Expression Assays; Invitrogen) and for the endogenous control 2-
microglobulin (2-MG; human B2M endogenous control, FAM/MGB
probe, TaqMan Endogenous Controls) were obtained from ABI. Sam-
ples (n 3) were assayed in duplicate in a total volume of 50 L, using
thermal cycling conditions of 2 minutes at 50°C and 10 minutes at 95°C
followed by 50 cycles of 95°C for 15 seconds and 60°C for 1 minute.
No-template controls were run in each assay to confirm lack of con-
tamination in reagents used for amplification. For data analysis, the
comparative threshold cycle (CT) method was adopted with the rela-
tive mRNA levels in normal subjects selected as the calibrator. The CT
was set in the exponential phase of the amplification plot. To normal-
ize the amount of target gene in each sample, the change in CT (CT)
was calculated by subtracting the average CT of the endogenous con-
trol from that of the target gene. The amount of TGFBI mRNA in FECD
was expressed relative to the amount present in the calibrator, using
the formula 2CT. Results were averaged, and the SEM was calcu-
lated. Statistical analysis with Student’s unpaired t-test was performed
(Excel 2002 for Windows XP; Microsoft). P  0.05 was considered to
be significant.
Immunocytochemical Localization of TGFBIp
and Clusterin
Normal and FECD corneas (Table 1, samples 16 and 17) were washed
in PBS and then fixed with 100% methanol for 10 minutes at20°C. All
subsequent steps were performed at room temperature. Corneas were
washed in PBS, then permeabilized for 10 minutes with 1% Triton
X-100 in PBS. Nonspecific binding was blocked using 4% bovine serum
albumin (BSA; Fisher Scientific, Pittsburgh, PA) in PBS for 10 minutes.
Corneas were incubated for 2 hours in rabbit polyclonal anti-clusterin
(Santa Cruz Biotechnology), diluted 1:50 in 4% BSA in PBS, and goat
polyclonal anti-TGFBIp (Santa Cruz Biotechnology), diluted 1:50 in 4%
BSA in PBS. Corneas were washed three times in PBS for 10 minutes
each and then incubated for 1 hour with fluorescein (FITC)-conjugated
donkey anti-goat IgG (Jackson ImmunoResearch, West Grove, PA)
diluted 1:200 in 4% BSA in PBS, rhodamine-conjugated donkey anti-
rabbit IgG (Jackson ImmunoResearch). Nuclear stain was performed
(TO-PRO-3; Invitrogen-Molecular Probes, Eugene, OR) diluted 1:2000
in PBS. Negative controls consisted of secondary antibody alone. After
they were washed in PBS, the corneas were placed endothelial side up
on slides in mounting medium (Vector Laboratories, Burlingame, CA).
Digital images were obtained by confocal microscope (TSC-SP2; Leica,
Bannockburn, IL). A z-series through the tissue was captured with a
step size of 0.2 m per image. Images were created by using a single
series or by collapsing z-series images onto a single-image plane by
projecting the maximum pixel intensity of the images.
RESULTS
Analysis of TGFBIp Isoform Expression in
Normal HCEC-DM Complex
Our previous studies comparing the proteome of FECD and
normal corneal endothelium revealed a marked overexpression
of TGFBIp in 2-D gels of FECD samples. In this study, we
further investigated TGFBIp expression and proteolytic pro-
cessing in normal human corneal endothelium. To characterize
TGFBIp expression, we pooled HCEC-DM protein extracts
from three normal donors and then subjected them to 2-D gel
electrophoresis followed by MALDI-TOF analysis. MALDI-TOF
identified TGFBIp in two areas of the gel. TGFBIp was identi-
fied as a series of spots with different pI migrating at two
different relative molecular weights. The first row of spots
identified as TGFBIp was located at the 68-kDa range within pI
3.0 to 8.0, as shown in brackets in Figure 1A. The major 68-kDa
TGFBIp fraction constituted a series of spots that most likely
represent different posttranslational modifications of TGFBIp.
The second series of spots identified as TGFBIp was at 39-kDa
range as shown in the lower brackets in Figure 1A. The 39-kDa
fragment was formed by six spots within pI 4.5 to 6.0, appar-
ently representing different posttranslational modification of
this TGFBIp form as well. The analysis of the remainder of the
spots on the 2-D gel did not reveal any additional TGFBIp
forms.
TGFBIp processing was studied by Western blot analysis
with antibodies reactive to two nonoverlapping parts of the
TGFBIp. Figure 1B depicts the diagram of anti-TGFBIp 120-170
(E-19) and anti-TGFBIp 626-683 (H-58) binding sites (molecular
weight range as provided by direct communication with Santa
Cruz Biotechnology, 2008). Immunostaining of 1-D gels with
anti-TGFBIp 120-170 and anti-TGFBIp 626-683 antibodies re-
FIGURE 1. TGFBIp expression in normal human HCEC-DM. Two-di-
mensional gel of HCEC-DM proteins pooled from five corneas of three
normal donors (A). The group of TGFBIp spots in the range of 68 and
39 kDa are indicated within brackets. Arrow: position of -actin. The
diagram of anti-TGFBIp 120-170 and 626-683 antibody binding is pre-
sented in a diagram (B). Western blot analysis of HCEC-DM protein
extracts resolved on 1-D gels with anti-TGFBIp 626-683 antibody (C)
and anti-TGFBIp 120-170 antibody (D). Long arrows: alignment of 68-
and 39-kDa TGFBIp fragments resolved on a 2-D gel and a Western blot.
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vealed a major band migrating at 68 kDa, which corresponded
to the full-size protein seen on the 2-D gel (Figs. 1C, 1D). The
anti-TGFBIp 626-683, which reacts with the C terminus of
TGFBIp, revealed several minor species of TGFBIp. The molec-
ular weights of the TGFBIp fragments found on the blots were
very similar to the previously published molecular weights of
TGFBIp fragments found in the protein extracts of the whole
corneas.16 Apart from the 68-kDa protein, anti-TGFBIp 626-683
recognized fragments of 57, 39, and 29 kDa. The 39-kDa frag-
ment corresponded to relative molecular weight of the minor
TGFBIp species seen on the 2-D gel. In contrast, anti-TGFBIp
120-170 which specifically reacts with the N terminus of
TGFBIp, did not detect these minor TGFBIp species. This differ-
ential staining suggests that minor TGFBIp species not de-
tected with the antibody against the N terminus represent
N-terminal deletions during the processing of the full-size pro-
tein.
Analysis of Age-Related Differences
To explore the age-related differences in TGFBIp expression,
six normal corneas at different ages were analyzed with the
Western blot analysis (Table 1, samples 2–7). The immuno-
staining with anti-TGFBIp 626-683 antibody to the C terminus
revealed a different staining pattern at different donor ages.
Figure 2A shows a representative blot of 2-, 15-, 64-, and
73-year-old donors, Figure 2B presents the densitometric com-
parison of all six samples based on normalization to -actin,
and Figure 2C presents the densitometric comparison of all six
samples based on normalization to total protein amount. The
comparison of protein levels between young and old donors
revealed similar results when TGFBIp content was normalized
to -actin or to total protein amount. The major band at 68-kDa
range was present in all ages. The 57-kDa band was present
only in older donors (P 0.04), indicating that this fragment of
TGFBIp is formed due to age-related proteolytic processing. On
average, there was a twofold increase in the 39-kDa band in
older individuals (P 0.03). The 29-kDa band was also present
only in older donors, but it showed variable intensity between
the specimens rendering it not statistically significantly ele-
vated in older HCEC-DM complexes (P  0.05) when TGFBIp
content was normalized to -actin, but was significantly ele-
vated in older samples (P  0.01) when TGFBIp content was
normalized to total protein content.
Differential Expression of TGFBIp Forms in
Normal and FECD Endothelium
Prior proteomic studies revealed a significant overexpression
of TGFBIp in FECD samples on 2-D gels.3 To investigate further
the differential expression of TGFBIp forms in FECD and nor-
mal HCEC-DM samples, Western blot analysis was performed
with antibodies against N and C termini of TGFBIp. The West-
ern blot data obtained from one pair of pooled samples (Table
1, sample 8) and four pairs of nonpooled samples (Table 1,
samples 9–12) was identical. Figure 3 shows a representative
blot with anti-TGFBIp for the C terminus (Fig. 3A) and a
representative blot with anti-TGFBIp for N terminus (Fig. 3B),
and Figure 3C presents the densitometric comparison. There
was a marked overexpression of most TGFBIp forms in FECD
specimens as opposed to normal subjects. On average, there
was a fivefold increase in the full-size protein (68-kDa band) in
FECD (P  0.04), as well as statistically significant increase in
minor TGFBIp species: the 57-kDa band (P  0.01) and 39-kDa
band (P  0.03) seen in FECD. The 29-kDa TGFBIp band was
increased in FECD endothelium but not at a statistically signif-
icant level (P  0.11). To compare protein levels between
FECD and normal specimens, results were normalized to -ac-
tin. The third column in the blots shows a normal specimen
loaded at a protein concentration twice as high as that in the
first two columns (Figs. 3A, 3B). Such higher loading was
performed to illustrate that both FECD and normal samples
generally exhibited the same TGFBIp species but at higher
levels in FECD when loading was normalized with -actin. The
29-kDa band had variable and faint presence in most normal
samples. The single band (68-kDa) that stained with anti-
TGFBIp 120-170 antibody was also markedly increased in
FECD, corroborating that the full-size TGFBIp is overexpressed
in FECD. No other bands were detected with this antibody to
the N terminus. FECD specimens demonstrated an increase in
levels of all these fragments but did not reveal any new or
unusual forms of TGFBIp.
Real-Time PCR Comparing TGFBI Expression
between Normal and FECD HCEC-DM
Proteomic analysis and Western blot data revealed the upregu-
lation of TGFBIp expression in FECD-affected corneal endothe-
lium. To investigate this difference, real-time PCR was per-
formed to evaluate the mRNA level of TGFBI. The PCR analysis
was performed by using previously optimized primers and
probes from ABI. Three different samples (samples 13–15)
were used to compare the TGFBI mRNA expression between
FECD and normal control subjects. The real-time PCR showed
an upregulation of TGFBI mRNA levels in FECD samples when
normalized with the internal control, 2-MG (Fig. 4). The
mean  SEM relative expression of TGFBI mRNA in the FECD
FIGURE 2. Age-related TGFBIp expression pattern. Representative
Western blot analysis comparing anti-TGFBIp 626-683 expression of
HCEC-DM extracts from normal 2-, 15-, 64-, and 73-year-old donors (A).
-Actin was used for normalization of protein loading. (B, C) Densito-
metric comparison of the average expression of TGFBIp fragments
(Table 1, samples 2–7). Bars, SD.
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group (2.35  0.23) was significantly higher than that in
normal subjects (1.31  0.38; P  0.04).
Colocalization of TGFBIp and Clusterin in FECD
Previous immunofluorescence studies showed a characteristic
CLU staining pattern in FECD endothelium with a rosette-type
clustering of endothelial cells around dark centers representing
corneal guttae. Indirect immunofluorescence analysis was per-
formed to investigate the relationship between TGFBIp and
CLU and to compare their localization in the endothelium of
normal and FECD donors. Figure 5 presents confocal images in
which the z-series was collapsed onto a single-image plane.
Figures 5A–D present confocal images of normal endothelium.
In normal tissue, a relatively uniform, punctate distribution of
TGFBIp and CLU was observed within the cytoplasm (Figs. 5A,
5B). Descemet’s membrane revealed bright fluorescence with
anti-TGFBIp antibody in all the specimens (data not shown). Of
note, the TGFBIp staining pattern in FECD endothelium (Figs.
5E–H) was different from that of normal HCECs. The dark areas
which did not contain the nuclei and were considered to be
corneal guttae had significant staining with both TGFBIp and
CLU in FECD samples (Figs. 5E–H, asterisks). In the centers of
guttae, TGFBIp colocalized with CLU most of the time (Figs.
5E, 5F, 5H, arrows). FECD tissue showed a much lower cell
density than normal tissue; diffuse but less bright TGFBIp
staining was visible even outside defined guttae, indicating the
staining of the Descemet’s membrane in areas devoid of cells.
Negative control experiments consisted of normal corneas
incubated with secondary antibody only and no TGFBIp or
CLU-positive staining of either cells or Descemet’s membrane
was observed under these conditions, indicating the specificity
of primary antibody staining (Figs. 5I–J).
To explore further the relationship between CLU and
TGFBIp staining single z-plane images were taken through the
guttae of FECD tissue at various depths (Fig. 6). A representa-
tive image through the apical part of endothelium at the level
of the nuclear plane showed intense intracellular, intranuclear,
and extracellular staining with CLU (Figs. 6B, 6D). The extra-
cellular staining was most abundant in the center of the de-
picted gutta. At this particular plane, there was only faint
staining in the center of the gutta with anti-TGFBIp antibody
(Fig. 6A). Figures 6E–H represents the images that were taken
1.0 m deeper into the cornea. At this plane, both TGFBIp and
CLU staining colocalized in the center of the gutta. Figures 6I–L
represents the images that were taken 3.8 m deeper into the
cornea beyond the nuclear plane of the same gutta. At this
plane, the center of the gutta had bright staining with anti-
TGFBIp antibody. The images taken at an even deeper level
showed significant TGFBIp staining at the level of Descemet’s
membrane (data not shown). Overall, the images manifested
specific colocalization of TGFBIp with CLU in the centers of
corneal guttae of FECD specimens. TGFBIp tended to localize
to the lower portions of guttae next to Descemet’s membrane
and CLU localized on top of the TGFBIp-stained areas.
DISCUSSION
The TGF--induced protein is mainly an extracellular matrix
protein that has a secretory signal sequence at the N terminus,
four homologous internal domains, and a cell-attachment site
(consisting of RGD amino acids) at the C terminus.6 The main
function of TGFBIp is attributed to its ability to bind various
ligands and mediate cell adhesion via the RGD sequence.7 In
our previous studies, we detected a marked overexpression of
clusterin and TGFBIp in FECD endothelium.3 In the present
study, we performed a targeted analysis of TGFBIp processing
in normal and FECD HCEC-DM and compared TGFBIp expres-
sion in young and old donors. The colocalization of TGFBIp
and CLU expression in guttae provided us with an insight into
the structural composition of these extracellular excrescences.
Proteomic analysis of normal HCEC-DM showed that TGFBIp
is abundantly expressed in the endothelial-DM complex. TGFBIp
has multiple threonine, tyrosine, and serine sites which allow
phosphorylation and thus posttranslational modification.16 On
2-D gels, 68- and 39-kDa TGFBIp fragments migrated as series
of spots with different pIs, most likely representing different
FIGURE 3. Comparison of TGFBIp expression patterns between FECD
and normal HCEC-DM. Representative Western blot analysis of anti-
TGFBIp 626-683 (A) and anti-TGFBIp 120-170 (B) comparing TGFBIp
expression in FECD and normal HCEC-DM (Table 1, sample 12). The
same normal sample was used in the second and third columns but
with twice as high loading in the third column. -Actin was used for
normalization of protein loading. (C) Densitometric comparison of the
average expression of TGFBIp fragments based on the anti-TGFBIp
626-683 results. Bars, SD. *P  0.04; **P  0.01; ***P  0.03; NS, not
statistically significant.
FIGURE 4. Comparison of TGFBI gene expression between FECD and
normal HCEC-DM by real-time PCR. Mean relative expression of mRNA
in normal subjects and in patients with FECD. Bars, SEM. *P  0.04.
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posttranslational modifications of TGFBIp. This finding is in
agreement with the other studies in which 2-D electrophoresis
was performed on the whole corneal extracts and identified
TGFBIp in multiple spots migrating at the same molecular
weight, but with different pIs.16 The fact that the 57- and
29-kDa fragments were repeatedly identified by Western blot
but not on the 2-D gels is most likely because these forms are
present in much lower concentrations and because MALDI-
TOF is not sensitive enough to identify them.
The analysis of TGFBIp content using antibodies against two
nonoverlapping parts of the protein revealed the presence of
C-terminal fragments of the protein that varied in relative
concentration with increasing age of the donors. In addition to
the major 68-kDa band corresponding to the full-size protein,
we identified a set of fragments that are most likely the prote-
olysis products characteristic for TGFBIp turnover in normal
HCEC-DM. It is possible that the TGFBIp fragments were cre-
ated from degradation by extracellular proteases. Nevertheless,
a more plausible explanation is the fragment formation from
normal TGFBIp turnover in corneal endothelium, since almost
identical molecular weight fragments were detected in the
study by Korvatksa et al.,16 in which N-terminal sequencing
and immunostaining were performed to characterize TGFBIp
content in the whole corneas. Our study showed an increase in
the levels of the 39-kDa fragment with increasing age of do-
nors. Of note, only 68- and 39-kDa bands were present
throughout the age range of donors. The other fragments (57-
and 29-kDa) appeared to be present in older age samples only,
implicating the age-related differences in normal TGFBIp turn-
over. The gradual thickening of Descemet’s membrane and
building of the posterior nonbanded layer with age is in agree-
ment with the increasing accumulation of TGFBIp which is
known to have a physiological interaction with collag-
ens.7,17,18 Previous studies performed on whole rabbit corneal
buttons showed an increase in steady state levels of TGFBI
mRNA that correlated with an increasing rate of collagen
accumulation during corneal morphogenesis.18 Several immu-
nohistochemical studies have localized TGFBIp in normal Des-
cemet’s membrane, posterior collagenous layer, and retrocor-
neal fibrous membrane, inferring its role as a structural element
of the aging and injured Descemet’s membrane.19–22 The exact
role of TGFBIp is not known, but its abundance in the extra-
cellular milieu of endothelium implies a substantial role in the
cell–Descemet’s membrane interaction.
A study comparing 2-D gels of FECD and normal donors
revealed an increase in TGFBIp spot intensity and number in
FECD samples.3 To analyze this difference further, we per-
formed Western blot analysis comparing TGFBIp expression in
normal and FECD HCEC-DM samples. Expression of 68-, 57-,
and 39-kDa fragments was statistically significantly higher in
the FECD HCEC-DM. The expression of the 29-kDa fragment
was elevated in FECD but not at a significant level. To corrob-
orate the increase of TGFBIp levels in FECD, we compared its
expression at the gene level between normal and FECD sam-
ples. The finding that levels of TGFBI mRNA were significantly
increased in FECD samples further substantiates the proteomic
data and indicates that the source of the differences stem from
increased gene transcription.
FIGURE 5. Colocalization of TGFBIp and CLU in normal and FECD
corneal endothelium. Representative confocal images of normal (A–D)
and FECD (E–H) endothelium in wholemounts of corneal tissue. Uni-
form TGFBIp staining (green) and CLU staining (red) was present in
the cytoplasm of normal corneal endothelium (A, B). (C) Staining of
nuclei (blue); (D) an overlay of the three images. (E–H, ✱) The guttae
that did not contain the nuclear stain. (E) TGFBIp staining (arrows) in
FECD-affected cells with increased brightness in the areas of guttae
(✱). (F) CLU staining (arrows) in the same tissue which colocalized to
the TGFBIp-stained areas in the centers of guttae (✱). (G) Stained
nuclei in the same tissue with nuclei surrounding guttae (✱); (H)
overlay of the three images colocalizing TGFBIp and CLU (arrows).
Negative control, incubated in secondary antibodies, shows no discern-
ible staining for TGFBIp and CLU in normal (I) and FECD (J) samples.
Final magnification, 400 with 3 zoom.
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Studies analyzing pathologic stromal deposits due to muta-
tion in the TGFBI gene have also identified an accumulation of
TGFBIp fragments in dystrophic corneas compared with nor-
mal ones.16,23,24 TGFBIp has been shown to colocalize and
coaggregate into these deposits, which were composed of
either amyloid or nonamyloid depending on the form of stro-
mal dystrophy.16 In addition to the increase in TGFBIp produc-
tion, the analysis of these corneas detected overexpression of
aberrant forms of TGFBIp that varied in their molecular weight
depending on the type of dystrophy. In our study of FECD
samples, we did not detect any aberrant or unusual forms of
TGFBIp that were not present in normal age-matched control
subjects, implying that probably there is no intrinsic mutation
in the TGFBI gene causing the accumulation of the protein.
This is in contrast to the findings in the stromal dystrophies
where overexpression of both normal and aberrant forms of
TGFBIp has been attributed to the TGFBI gene mutations.16
The immunohistologic analysis revealed an interesting pat-
tern of CLU and TGFBIp colocalization in the guttae, the
excrescences characteristic of Fuchs corneal dystrophy. The
staining for TGFBIp was prominent throughout Descemet’s
membrane and showed a marked increase in intensity at the
centers of the guttae. CLU was also present in the centers of
the guttae but on top of TGFBIp staining, closer to the apical
side of the endothelium. The diagram in Figure 7 shows a
schematic representation of the relationship of CLU and
TGFBIp role in guttae formation. This is the first known study
to colocalize CLU and TGFBIp in these pathologic extracellular
matrix deposits. There is no known correlation in the literature
between clusterin and TGFBIp. It is known, though, that CLU
overexpression at the times of cellular stress (including oxida-
tive stress) causes the cells to aggregate via cell–cell and
cell–substratum interactions.5 The driving force of these inter-
actions oftentimes is the production of cell adhesive molecules
and junctional complexes. In a renal injury model, such inter-
actions are capable of preserving the integrity of the renal
epithelial barrier.25,26 When the cell–matrix interactions are
disrupted, a form of apoptosis called anoikis ensues. Similarly
in FECD, there is an overproduction of the cell-adhesion mol-
FIGURE 6. Localization of TGFBIp
and CLU in the gutta. Representative
confocal images taken through a sin-
gle, 0.2-m-thick z-plane of a gutta at
the level of the endothelial nuclear
plane (A–D), 1.0 m (E–H), and 3.8
m (I–L) deeper toward the Desce-
met’s membrane. Images were taken
after immunostaining for TGFBIp
(green) (A, E, I) and CLU (red) (B, F,
J) and nuclear staining (blue) (C, G,
K). (D, H, L) Overlay of the three
images. Final magnification, 400
with 8 zoom.
FIGURE 7. Schematic representation of the role TGFBIp and CLU in
guttae formation. There is a gradually increasing production of TGFBIp
and CLU in the centers of guttae. TGFBIp accumulates in close prox-
imity to Descemet’s membrane, whereas CLU forms aggregates on top
of the TGFBIp deposits at the endothelial cell level. Both TGFBIp and
CLU colocalized in the middle of the guttae (inset).
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ecule, TGFBIp in the setting of the prolonged tissue injury and
pathologic CLU overexpression. It is possible that the endothe-
lial cells under stressors of the dystrophic degeneration are
clumping via the action of CLU and are adhering to their
substratum via the action of TGFBIp. The attempt of the cells
to attach to their substratum is progressively disrupted during
guttae formation, thus rendering the cells susceptible to apo-
ptosis.
In conclusion, there is an increased production and modi-
fication of TGFBIp in the aging HCEC-DM complex. The in-
crease in TGFBIp production is even greater in FECD com-
pared with the age-matched normal control subjects. The
proaggregative protein CLU and the proadhesive protein
TGFBIp colocalize in the centers of guttae. Even though such
findings cannot infer the functional role of these proteins in the
pathogenesis of the dystrophy, it provides us with a better
understanding of the major culprits involved in the aberrant
cell–extracellular matrix interactions.
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